What is the purpose of this trial?
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
Ages: 18 years and older
Dates: 05/19/2017 - 11/01/2019
Last Updated: 05/21/2017
Study HIC#: 2000020437